Some patients report noticeable improvements in pain, mobility, and function within 2 to 4 weeks, while others can take up to 12 weeks or longer to see measurable progress
Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer
Found in large amounts in muscles, it is a key element in the transport of fatty acids to the mitochondria, where they are used in metabolic processes involved in energy production
Microdosing protocols Microdosing semaglutide involves very small doses, sometimes daily
GLP1s+ Summary In the last 30 years, weve gone from no GLP1s+ or truly scalable weight loss treatments to having treatments that: Efficacy: help patients lose 22% (and still rising) of their weight on average, up from 3-5% Disease Expansion: are approved for diabetes, obesity, cardiovascular disease and soon likely kidney disease and sleep apnea, with more conditions under study Frequency: are taken 1x/week, down from 2x/day (52 times per year versus 730) Form Factor: can be taken orally with more effective options on the horizon Improving the form factor, reducing the burden placed on the patient, all while maintaining and increasing efficacy across weight loss and other cardiometabolic measures, these are incredible feats of science that will benefit humanity in ways we cannot yet comprehend, especially once prices decline
